Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

August 11, 2017: By Jon Swedien

Valeant PharmaceuticalsValeant’s Pharmaceuticals’ Bausch + Lomb segment posted revenues of $1.24 billion in Q2-2017, a decrease of 3 percent (+1 percent, cc) compared with $1.28 billion for Q2-2016, the company reported Aug. 8.

In an earnings call, Valeant Chairman and CEO Joseph Papa said the Bausch + Lomb/International segment represented 56 percent of Valeant’s revenues in the quarter. He noted B+L’s strong performance in China (+4 percent, +9 percent cc), driven by volume.

Valeant posted total revenues of $2.23 billion in Q2-2017, an 8 percent decrease (-5 percent, cc) compared with Q2-2016.

The company said it remained committed to lowering its debt and had reduced the total by more than $4.8 billion since Q1-2016.

Its total long-term debt is currently $28.5 billion.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

FDA Warns that Vancomycin Eye Injections May Lead to Blindness

Alcon to Launch Clareon IOL at ESCRS Meeting

Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

Valeant Launches $1 Billion Private Senior Notes Offering

STAAR Surgical Appoints Scott Barnes, MD, as New CMO

Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

Maryland Team Wins First Phase of NEI Contest to Create Human Retina

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022